CytoSorbents Corporation (CTSO)

[cars100cars]

Look for a good earnings report as we move into May. DC's conference call is ahead by only a few weeks. Sales in Germany should gain greater strength with solid insurance reimbursement now approved. More docs and more hospitals there will be adding CytoSorb to ICU treatment and cardiac procedures. Distributor sales from Fresenius will also add to upward pressures on accelerating revenues. Fresenius has been named in multiple case histories, which they must be using to market their own machines with CytoSorb. The combo technologies are highly effective. Considering new distributors, too, that are adding countries in Africa, with growth in Russia, India and other emerging distributor sales. The sales rate projected ahead after Q117 number release should indicate roughly +/- $18 million in sales annually, which would represent about 100% growth in revenues in 2017. It may be even more. After all, to accomplish this, quarterly sales only need to rise 20% in Q1. And, then replicate that each quarter...this should be easy for CTSO to do given it is simply the persistence of the trend already in place. By the 4Q17, sales could be roughly $5.5 million. Do the math. Look ahead. Chan has also said gross margin can increase to +/- 80% -- up from the current 60%+. This company is gradually growing into a cash cow. This is why 2.2 million shares at a discounted price got snapped up in a matter of days.